JamesEdwardWooldridgeMD

Physician

Dr. Wooldridge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1996
Tulane University School of MedicineClass of 1992

PubMed

67 citations
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez
Cancer Discovery. 2021-07-29
128 citations
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
Brian K. Link, Zuhair K. Ballas, Daniel Weisdorf, James E. Wooldridge, Aaron D. Bossler
Journal of Immunotherapy. 2006-09-01
226 citations
Improved Survival of Follicular Lymphoma Patients in the United States
Wade T. Swenson, James E. Wooldridge, Charles F. Lynch, Valerie L. Forman-Hoffman, Elizabeth A. Chrischilles
Journal of Clinical Oncology. 2005-08-01

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009January 4th, 2023
Checkmate Pharmaceuticals Announces Additions to Management TeamOctober 15th, 2019